Current Treatment Options in Neurology

, Volume 4, Issue 5, pp 335–342

Headache recurrence and treatment

  • Sheena K. Aurora
  • John Dempsey
Article
  • 27 Downloads

Opinion statement

The definition of recurrence includes the following: any headache occurring after a headache-free state at 2 hours and within 24 hours after intake of drug; a headache that has never been studied systematically; a headache that may not be an outcome of drug treatment; a headache that may be due to the inherent nature of migraine and individual patient characteristics such as duration of attack; and headache for which effective treatment may be a re-dose of the initial medication or addition of steroidal or nonsteroidal anti-inflammatory medications.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Ferrari M: How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999, 19(suppl):2–8.PubMedGoogle Scholar
  2. 2.
    Goldstein DJ, Offen WW, Moster MB: Efficacy definitions for migraine studies. Cephalalgia 1999, 19:248–249.PubMedCrossRefGoogle Scholar
  3. 3.
    Göbel H, Boswell D, Winter P, Crisp A: A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan [abstract]. Cephalalgia 1997, 17:426.Google Scholar
  4. 4.
    Pfaffenrath V, Cunin G, Sjonell G, Prendergast S: Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998, 38:184–190.PubMedCrossRefGoogle Scholar
  5. 5.
    Pini LA, Sternieri E, Fabbri L, et al.: High efficacy and low frequency of headache recurrence after oral sumatriptan. J Int Med Res 1995, 23:96–105.PubMedGoogle Scholar
  6. 6.
    Rapoport AM, Visser WH, Cutler MD, et al.: Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995, 45:1505–1509.PubMedGoogle Scholar
  7. 7.
    Scott RJ, Aitchison WRC, Barker PR, McLaren GI: Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice. Q J Med 1996, 89:613–622.Google Scholar
  8. 8.
    Dahlöf C, Diener HC, Goadsby PJ, et al.: Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicenter, dose-range finding study. Eur J Neurol 1998, 5:535–543.PubMedCrossRefGoogle Scholar
  9. 9.
    Rapoport AM, Ramadan NM, Adelman JU, et al.: Optimizing the dose of zolmitriptan for the acute treatment of migraine: a multicenter, double blind, placebo-controlled, dose range-finding study. Neurology 1997, 49:1210–1218.PubMedGoogle Scholar
  10. 10.
    Solomon GD, Cady RK, Klapper JA, et al.: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine: the 042 Clinical Trial Study Group. Neurology 1997, 49:1219–1225.PubMedGoogle Scholar
  11. 11.
    Visser WH, Klein KB, Cox RC, et al.: 311C90, a new central and peripherally acting 5-HT 1D receptor agonist in the acute oral treatment of migraine: a double blind, placebo-controlled, dose-range finding study. Neurology 1996, 46:522–526.PubMedGoogle Scholar
  12. 12.
    Ahrens S, Farmer MV, Williams DL, et al.: Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 1999, 19:525–530.PubMedCrossRefGoogle Scholar
  13. 13.
    Bomhof M, Paz J, Legg N, et al.: Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine. Eur Neurol 1999, 42:173–179.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldstein J, Ryan R, Jiang K, et al.: Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 5 mg and 50 mg in migraine. Headache 1998, 38:737–747.PubMedCrossRefGoogle Scholar
  15. 15.
    Teall J, Tuchman M, Cutler N, et al.: Rizatriptan for the acute treatment of migraine and migraine recurrence: a placebo-controlled, outpatient study. Headache 1998, 38:281–287.PubMedCrossRefGoogle Scholar
  16. 16.
    Tfelt-Hansen P, Teall J, Rodriguez F, et al.: Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998, 38:748–755.PubMedCrossRefGoogle Scholar
  17. 17.
    Dahlöf C, Winter P, Whitehouse H, Hassani H: Randomized, double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine [abstract]. Neurology 1997, 48:A85.Google Scholar
  18. 18.
    Klassen A, Elkind A, Asgharnejad M, et al.: Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double blind, placebo-controlled, parallel-group study. Headache 1997, 37:640–645.PubMedCrossRefGoogle Scholar
  19. 19.
    Mathew NT, Asgharnejad M, Peykamian M, et al.: Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double blind, placebo-controlled, crossover study. Neurology 1997, 49:1485–1490.PubMedGoogle Scholar
  20. 20.
    Pascual J, Falk RM, Piessens F, et al.: Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double blind, placebo-controlled study. Cephalalgia 2000, 20:588–596.PubMedCrossRefGoogle Scholar
  21. 21.
    Spierings ELH, Gomez-Mancilla B, Grosz DE, et al.: Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double blind randomized parallel-group, optimum dose comparison. Arch Neurol 2001, 58:944–950.PubMedCrossRefGoogle Scholar
  22. 22.
    Pascual J, Falk RM, Docekal P, et al.: Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001, 45:206–213.PubMedCrossRefGoogle Scholar
  23. 23.
    Dahlöf C, Tfelt-Hansen P, Massiou H, Fazekas A: Dose finding placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001, 57:1811–1817.PubMedGoogle Scholar
  24. 24.
    Millson D, Tepper S: Issue relating to the assessment of migraine recurrence following triptan therapy [letter]. Eur J Neurol 1999, 6:525–526.PubMedCrossRefGoogle Scholar
  25. 25.
    Goadsby PJ: Evaluating specific acute headache therapies: recurrence and tolerability. Paper presented at: 52nd Annual Meeting of the American Academy of Neurology; San Diego, CA. May 2, 2000;Google Scholar
  26. 26.
    Visser WH, Burggraaf J, Muller LM, et al.: Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 1996, 60:452–460.PubMedCrossRefGoogle Scholar
  27. 27.
    Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD: Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996, 16:264–269.PubMedCrossRefGoogle Scholar
  28. 28.
    Weiller C, May A, Limmroth V, et al.: Brainstem activation in spontaneous human migraine attacks. Nature Med 1995, 1:658–660.PubMedCrossRefGoogle Scholar
  29. 29.
    Sheftell F, O’Quinn S, Watson C, et al.: Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000, 40:103–110.PubMedCrossRefGoogle Scholar
  30. 30.
    Lance JW: Summing-up. In Migraine: Pharmacology and Genetics. Edited by Sandler M, Ferrari MD, Harnett S. London: Chapman and Hall; 1996:300–308.Google Scholar
  31. 31.
    Ferrari MD, Lipton RB, McCarroll KA, Vandormael K: Lines CR. 24-hour sustained pain free status after rizatriptan and other triptans: a comparison. Headache 2000, 40:407–408.Google Scholar
  32. 32.
    Ferrari M, Roon K, Lipton R, Goadsby PJ: Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668–1675. Extensive scientific review of currently available triptans.PubMedCrossRefGoogle Scholar
  33. 33.
    Cull RE, Price WH, Dunbar A: The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. J Neurol Neurosurg Psychiatry 1997, 62:490–495.PubMedCrossRefGoogle Scholar
  34. 34.
    Krymchantowski AV: Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquitar 2000, 58:428–430. Important placebo-controlled study using naratriptan.Google Scholar
  35. 35.
    Krymchantowski AV, Adriano M, Fernandes D: Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999, 19:186–187.PubMedCrossRefGoogle Scholar
  36. 36.
    Krymchantowski AV, Barbosa JS: Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with an NSAID. Arq Neurosiquitar 2001, 59:708–711.Google Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Sheena K. Aurora
    • 1
  • John Dempsey
    • 1
  1. 1.Swedish Neuroscience InstituteSwedish Headache CenterSeattleUSA

Personalised recommendations